Form 4 for BLFS BIOLIFE SOLUTIONS INC
Accepted 2025-05-30 00:00:00 ET · period of report 2025-05-28 · accession 0001628280-25-028700 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-05-30 | 2025-05-28 | BLFS | Mathew Aby J. | EVP, CSO | S - Sale | $22.46 | -521 | 308.5K | -0.2% | -$11.7K | |
| 2025-05-30 | 2025-05-29 | BLFS | Mathew Aby J. | EVP, CSO | A - Grant | — | +45.3K | 353.8K | +15% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-05-28 | S | D | 521 | $22.46 | 308,486 | D | — | — | |
| 2 | Common | Common Stock | 2025-05-29 | A | A | 45,269 | — | 353,755 | D | — | — | (F2) The restricted stock was granted pursuant to the BioLife Solutions 2023 Performance Incentive Plan (the "2023 Plan") and fully vests on the fourth anniversary of the measurement date of 05-29-2025. |